Nascent Biotech, Inc. NBIO
0.00 USD 0.00 (+50.00%)
At closeNov 9, 2026, 4:00 PM EST
0.0005 Day range 0.0005
0.0001 52-week range 0.1345
- YTD
- -50.00%
- 1 year
- 0.00%
News
defenseworld.net Nascent Biotech (OTCMKTS:NBIO) Stock Price Crosses Above 50 Day Moving Average – Time to Sell? Nascent Biotech, Inc. (OTCMKTS:NBIO - Get Free Report)'s share price passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.00 and traded as…
accesswire.com Nascent Biotech Presents at the July Emerging Growth Conference Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent…
accesswire.com Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal…
accesswire.com Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal…
accesswire.com Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the…
accesswire.com Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a…
accesswire.com Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the…
accesswire.com Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the…
accesswire.com Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is…
accesswire.com Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused…
accesswire.com Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome…
accesswire.com Marble Arch Research Publishes Analyst Research Report on Nascent Biotech VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of…
seekingalpha.com Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights…
accesswire.com Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the…
accesswire.com Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of…
accesswire.com Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of…
accesswire.com Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of…
accesswire.com Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of…
accesswire.com Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of…